First observation of dupilumab efficacy in an infant with SAM (severe dermatitis, multiple allergies and metabolic wasting) syndrome

J Eur Acad Dermatol Venereol. 2023 Oct;37(10):e1200-e1202. doi: 10.1111/jdv.19185. Epub 2023 May 18.

Authors

R W Körner¹, C Velmans², G Dückers³, I Tantcheva-Poór⁴

Affiliations

¹ Department of Pediatrics, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany.
² Institute of Human Genetics, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany.
³ Helios Klinikum, Children's Hospital, Krefeld, Germany.
⁴ Department of Dermatology and Venereology, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany.

PMID: 37170963
DOI: 10.1111/jdv.19185

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Dermatitis*
Humans
Hypersensitivity*
Infant
Severity of Illness Index
Treatment Outcome
Wasting Syndrome* / metabolism

Substances

dupilumab
Antibodies, Monoclonal, Humanized